Current stock page

Stock Analysis

Cytokinetics, Incorporated (CYTK) Stock Analysis

Cytokinetics, Incorporated (CYTK) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

CYTK Stock Analysis Summary

Cytokinetics, Incorporated (CYTK) currently has an AIQ Score of 40/100, indicating a bearish setup. Risk is the strongest factor at 56/100. Momentum is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

CYTK at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$56.13
AIQ Score40/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$7.8B
P/E Ratio (TTM)-9.31
Forward P/E—
EPS (Q3 FY2026)-$1.37
Revenue (Q3 FY2026)$47.56M
Dividend Yield (TTM)0.00%
Beta1.01
Volume1.01M
52-week range$53.55-$88.31
RSI 1438.17
50-Day SMA$64.11
200-Day SMA$69.78
Analyst Price Target$99.33
Next EarningsFeb 23, 2027
As of Nov 13, 2026 · Market close

CYTKCytokinetics, Incorporated

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$56.13−$0.03 (−0.05%)

Latest quote

  • Momentum
    28
  • Value
    41
  • Quality
    46
  • Risk resilience
    56
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

CYTK Stock Analysis Summary

Cytokinetics, Incorporated (CYTK) currently has an AIQ Score of 40/100, indicating a bearish setup. Risk resilience is the strongest factor at 56/100. Momentum is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, CYTK has AIQ Score of 40/100 with Risk resilience base of 56/100 and fading Momentum at 28/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Risk resilience (56/100) leads while Momentum (28/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.05% stock move · CYTK classified in Biotechnology.

Current Evidence

BearishCYTK is in a bearish AIQ regime; Risk resilience is the strongest visible factor at 56/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is CYTK Bullish or Bearish Right Now?

CYTK currently has a bearish overall setup. Risk Resilience is the strongest factor at 56/100, while Momentum is weakest at 28/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +76.97% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 41/100.
  • - Momentum is weak at 28/100.
  • - Price is -19.56% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (38 vs 0).

Current Consensus

CYTK's Technical Analysis Consensus is currently Strong Sell, with 0 buy, 8 neutral, and 38 sell votes. CYTK's 14-day RSI is 38.17, which places the stock in a weaker momentum range. CYTK's beta is 1.01, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in CYTK?

The largest recent change in CYTK is Momentum moving down by 5.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-5.0
Quality
+1.0
Risk
+0.0

What Would Change the CYTK Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

CYTK Decision Framework

Public evidence layers, setup checks, and risk context for Cytokinetics, Incorporated.

Cytokinetics, Incorporated (CYTK) Stock Analysis

Cytokinetics, Incorporated has an AIQ Score of 40/100 in a Bearish regime. Risk is strongest at 56/100. Beta is 1.01, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextCYTK is in a Bearish AIQ regime with score 40/100.
Signal ConflictThe primary conflict is that risk leads at 56/100 while momentum lags at 28/100.
Factor EvidenceMomentum 28/100 · Value 41/100 · Quality 46/100 · Risk 56/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Risk is the strongest factor at 56/100.

TimingFail

Momentum is 28/100 and RSI (14) is 38.2.

Regime fitFail

CYTK is in a Bearish regime at 40/100.

Risk controlWait

Risk factor is 56/100 with beta 1.01 and annual volatility 43.65%.

ConflictWait

Current conflict: risk leads at 56/100 while momentum lags at 28/100.

AIQ Score
40/100
Price
$56.13
Beta
1.01
RSI (14)
38.2

CYTK Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

CYTK Fundamentals

CYTK valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$47.56M
Net income
-$190.07M
Free cash flow
-$124.72M
View full CYTK fundamental analysis

CYTK Technical Analysis

CYTK technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
38.17
Price vs SMA-50
-12.45%
View full CYTK technical analysis

CYTK Stock Catalysts

Track CYTK earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 23, 2027
Analyst target
$99.33
News items
5
View CYTK earnings and stock catalysts

CYTK Dividend Analysis

CYTK dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View CYTK dividend history and analysis

CYTK Financial Data

CYTK revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$47.56M
EPS
-$1.37
Periods
8
View CYTK financials

CYTK Risk Analysis

CYTK volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.01
Risk score
56/100
1Y volatility
43.65%
View CYTK risk analysis

CYTK Stock News

CYTK stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read CYTK stock news

CYTK vs Biotechnology Peers

Current peer cohort: CYTK · DFTX · DNTH · DYN · ELVN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
CYTK
Current stock
40/10041/10028/10056/100-0.2343.65%Current
DFTX
Definium Therapeutics, Inc.
59/100—64/10044/1001.6177.71%CYTK vs DFTX
DNTH
Dianthus Therapeutics, Inc.
56/100—58/10058/1001.8259.79%CYTK vs DNTH
DYN
Dyne Therapeutics, Inc.
48/100—52/10042/1000.1163.89%CYTK vs DYN
ELVN
Enliven Therapeutics, Inc.
71/100—66/10056/1001.4378.19%CYTK vs ELVN
Pairwise Compare links: DFTX · DNTH · DYN · ELVNCYTK vs DFTXCYTK vs DNTHCYTK vs DYNCYTK vs ELVNCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a CYTK stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for CYTK: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-9.31
As of Nov 13, 2026
Revenue growth
2356.46%
Gross margin
91.00%
Current debt / equity
-3.96
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$47.56M
Quarter net income
-$190.07M
Quarter free cash flow
-$124.72M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Bearish
RSI 14
38.17
MACD
-2.32

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
56/100
Beta
1.01
Annual volatility
43.65%
Max drawdown
-38.47%

CYTK Stock FAQ

What is CYTK stock price today?

Cytokinetics, Incorporated's current stock price is $56.13. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is CYTK bullish or bearish right now?

CYTK's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is CYTK's market cap?

CYTK's market cap is $7.8B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is CYTK's current P/E ratio?

CYTK's current P/E ratio is -9.31 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is CYTK's RSI?

CYTK's 14-day RSI is 38.17 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is CYTK above its 50-day and 200-day moving averages?

CYTK is -12.45% from its 50-day SMA and -19.56% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is CYTK's next earnings date?

CYTK's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does CYTK pay a dividend?

CYTK's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.